rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NAMSW
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NewAmsterdam Pharma at Jefferies: 2027 trial data in focus
      14h agoInvesting.comNAMSWJEF
      NewAmsterdam Pharma at Stifel 2026 Healthcare Conference 2026: trial data build
      Nov 11Investing.comNAMSNAMSWSF
      Cantor raises NewAmsterdam Pharma stock price target to $61
      Nov 11Investing.comNAMSNAMSW
      The Billionaire-Backed Pharma Play Sitting on a $640M Cash Pile at 52-Week Lows
      Nov 7Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 6Yahoo FinanceNAMSNAMSW
      Newamsterdam Pharma stock hits 52-week low at 19.1 USD
      Nov 5Investing.comNAMSNAMSW
      Stifel reiterates Buy on NewAmsterdam Pharma stock, $50 target
      Nov 4Investing.comNAMSNAMSWSF
      Truist reiterates buy on NewAmsterdam Pharma stock ahead of trials
      Nov 4Investing.comNAMSNAMSWTFC
      NewAmsterdam Pharma receives EU approval for obicetrapib drugs
      Nov 4Investing.comNAMSNAMSW
      NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
      Nov 4Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
      Nov 3Yahoo FinanceNAMSW
      Newamsterdam Pharma stock hits 52-week low at 19.57 USD
      Oct 23Investing.comNAMSNAMSW
      Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
      Oct 13Yahoo FinanceNAMSNAMSW
      Newamsterdam Pharma stock hits 52-week low at 21.02 USD
      Oct 8Investing.comNAMSNAMSW
      RBC Capital cuts NewAmsterdam Pharma stock price target on trial risk
      Oct 5Investing.comNAMSNAMSW
      RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk
      Oct 5Yahoo FinanceNAMSNAMSW
      NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
      Oct 5Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

      Oct 2Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

      - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- NAARDEN, the Netherlands and MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a lat

      Sep 29Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

      NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe. These are the products’ first global approvals. The medicines lower low-density lipoprotein cholesterol, or LDL-C, commonly called […]

      Sep 23Yahoo FinanceNAMSNAMSW
      Stifel reiterates NewAmsterdam Pharma stock rating on EU approval
      Sep 21Investing.comNAMSNAMSW
      European Commission approves obicetrapib for cholesterol treatment
      Sep 21Investing.comNAMSNAMSW
      NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
      Sep 21Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run

      NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value. With the stock now some distance below its earlier highs, the issue is whether the balance sheet still backs up where the price sits today. Over the past 3 years, NewAmsterdam Pharma has returned about 139%, which now puts real pressure on the numbers to show that book value keeps...

      Sep 20Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock
      Sep 15Investing.comNAMSNAMSW
      NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test
      Sep 10Investing.comNAMSNAMSW
      NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push
      Sep 9Investing.comNAMSNAMSWWFC
      Newamsterdam Pharma stock hits 52-week low at 23.02 USD
      Sep 9Investing.comNAMSNAMSW
      Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

      Detailed price information for Newamsterdam Pharma Company N.V. (NAMS-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailNAMSNAMSW
      Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)

      Detailed price information for Amgen Inc (AMGN-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailNAMSNAMSW
      NewAmsterdam Pharma options activity points to institutional PREVAIL trial positioning
      Sep 8Investing.comNAMSNAMSW
      NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS)

      NewAmsterdam Pharma is rated a Hold and has seen a near 40% stock pullback post-Merck’s Lipfendra approval. Read more on NAMS stock here.

      Sep 8Seeking AlphaNAMSNAMSW
      Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure
      Sep 8Investing.comNAMSNAMSW
      NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’

      Sep 3Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

      NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the

      Sep 2Yahoo FinanceNAMSNAMSW
      NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

      NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib de

      Aug 26Yahoo FinanceNAMSNAMSW

      This is the newest page. Registered accounts read further back.